ReleaseWire

GlobalData's clinical trial report, "Myoclonus Global Clinical Trials Review, H2, 2014" provides data on the Myoclonus clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Myoclonus. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Myoclonus. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

Global Markets Direct's, 'OriBase Pharma - Product Pipeline Review - 2014', provides an overview of the OriBase Pharma's pharmaceutical research and development focus.

Accutrition is now offering TravaCor 120 on their website. The natural health supplements retailer is excited to provide this product from NeuroScience which has been shown to safely improve mood and irritability. Many patients who experience mood imbalances hesitate to rely on antidepressants and other heavy prescriptions if they are not diagnosed with any serious condition. TravaCor is not meant to treat depression, but will ease occasional anxiousness and restlessness, helping the user stay calm, feel better, and sleep easier.

Hypertension, also referred as arterial hypertension or high BP, is a chronic medical condition in which the arterial blood pressure is elevated to an undesired level. Lifestyle habits such as diet, exercising, and smoking are the major causes of hypertension. Hypertension can damage organs and lead to several illnesses such as renal failure, aneurysm, heart failure, stroke, and heart attack. There are two types of hypertension: primary or essential and secondary.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

GlobalData's clinical trial report, "Metachromatic Leukodystrophy (MLD) Global Clinical Trials Review, H2, 2014" provides data on the Metachromatic Leukodystrophy (MLD) clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Metachromatic Leukodystrophy (MLD). It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Metachromatic Leukodystrophy (MLD). This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

MarketLine's Company Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage.

Global Markets Direct's, 'Sanwa Kagaku Kenkyusho Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the Sanwa Kagaku Kenkyusho Co., Ltd.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Qu Biologics Inc. - Product Pipeline Review - 2014', provides an overview of the Qu Biologics Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'AC Immune SA - Product Pipeline Review - 2014', provides an overview of the AC Immune SA's pharmaceutical research and development focus.

The Fujirebio, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital raisings, venture capital investments, ownership and partnership transactions undertaken by Fujirebio, Inc. since January 2007.

Global Markets Direct's, 'Arno Therapeutics, Inc. - Product Pipeline Review - 2014', provides an overview of the Arno Therapeutics, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Myocardial Infarction - Pipeline Review, H2 2014', provides an overview of the Myocardial Infarction's therapeutic pipeline.

Global Markets Direct's, 'Nuformix Ltd - Product Pipeline Review - 2014', provides an overview of the Nuformix Ltd's pharmaceutical research and development focus.

Hormone replacement therapy, also known as hormone therapy, is a means of replacing hormones that are no longer being produced by the body. This type of therapy is usually initiated at menopause or may be started while a woman is in the perimenopausal phase, nearing menopause. Hormone replacement therapy replenishes the hormones required by the human body to function by using bio-identical hormones. The therapy contains estrogen and progesterone, and in some cases testosterone, to reduce symptoms of menopause. This replacement therapy may also protect against osteoporosis, reduce the risk of coronary heart disease, and may prevent or delay the onset of Alzheimer's disease. Replacement therapy can also increase the chance of developing more serious health complications such as blood clots, breast cancer, uterine cancer, and bowel cancer.

Global Markets Direct's, 'Amorfix Life Sciences Ltd. - Product Pipeline Review - 2014', provides an overview of the Amorfix Life Sciences Ltd.'s pharmaceutical research and development focus.

Global Markets Direct's, 'MolMed S.p.A. - Product Pipeline Review - 2014', provides an overview of the MolMed S.p.A.'s pharmaceutical research and development focus.

GlobalData's clinical trial report, "Hypoxic-Ischemic Encephalopathy Global Clinical Trials Review, H2, 2014 provides data on the Hypoxic-Ischemic Encephalopathy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Hypoxic-Ischemic Encephalopathy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Hypoxic-Ischemic Encephalopathy. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Tribulus Terrestris which is one of the newest trend in the health and wellness community today has its popularity skyrocket since last year. Known to be as a sex drive booster, people who have used it experienced numerous positive effects while using it. Tribulus Terrestris is basically a plant which is commonly found in various parts of the globe including South America and Asia. It is also known as Puncture Vine and has been used in traditional medicine. However, there are researches that reported that Tribulus Terrestris may have the potential to be an excellent testosterone booster.

Global Markets Direct's, 'Vaxon Biotech - Product Pipeline Review - 2014', provides an overview of the Vaxon Biotech's pharmaceutical research and development focus.

Global Markets Direct's, 'Diabetic Gastroparesis - Pipeline Review, H2 2014', provides an overview of the Diabetic Gastroparesis's therapeutic pipeline.

Global Markets Direct's, 'Enanta Pharmaceuticals, Inc. - Product Pipeline Review - 2014', provides an overview of the Enanta Pharmaceuticals, Inc.'s pharmaceutical research and development focus.

Global Markets Direct's, 'Mucosis B.V. - Product Pipeline Review - 2014', provides an overview of the Mucosis B.V.'s pharmaceutical research and development focus.

ACCESS PHARMACEUTICALS, INC., a developer of new products for oncology supportive care, announced today that it has received 510(K) marketing clearance from the U.S. Food and Drug Administration (FDA) for ProctiGard™, its novel treatment for symptomatic management of rectal mucositis. The Company indicated its development of ProctiGard™ is a direct response to dialogue with the oncology community that is looking for better, more treatment options for rectal mucositis and radiation proctitis, a debilitating oncology side effect. Access believes that ProctiGard is a first-in-class treatment option that addresses a significant unmet medical need. Access currently holds global commercialization rights for ProctiGard.